The Oxford single-dose rabies vaccine is an encouraging development in the fight against the illness.
The virus that causes rabies is spreadable and dangerous to human life. Although there are rabies instances all around the world, they are most common in portions of Africa, India, and China. The young are especially at risk; over 40% of cases involve children under 15.
The importance of a novel, single-dose vaccine stems from this. The Phase 1 clinical study of the University of Oxford's novel rabies vaccine, ChAdOx2 RabG, had encouraging findings. The novel rabies vaccination had never before been tested on humans.
Researchers used the RAB001 trial to examine the safety and immunological responses to the vaccination by measuring levels of rabies neutralizing antibodies, key evidence of rabies vaccine efficacy. Twelve volunteers all participated in the study. Three subjects received a...